^
CDKN2A overexpression
Estrogen Receptor Positive Breast Cancer
CDK6 inhibitor
Resistant
:
D
Nat Commun - 3 weeks - (New D)
CDKN2A overexpression
Estrogen Receptor Positive Breast Cancer
CDK4 inhibitor
Resistant
:
D
Nat Commun - 3 weeks - (New D)
HER-2 amplification
Hormone Receptor Positive Breast Cancer
trastuzumab-qyyp
Sensitive
:
A1
HER-2 overexpression
Hormone Receptor Positive Breast Cancer
trastuzumab-qyyp
Sensitive
:
A1
HER-2 amplification
Hormone Receptor Positive Breast Cancer
trastuzumab-dttb
Sensitive
:
A1
HER-2 overexpression
Hormone Receptor Positive Breast Cancer
trastuzumab-dttb
Sensitive
:
A1
HER-2 amplification
Hormone Receptor Positive Breast Cancer
trastuzumab-dkst
Sensitive
:
A1
HER-2 overexpression
Hormone Receptor Positive Breast Cancer
trastuzumab-dkst
Sensitive
:
A1
HER-2 amplification
Hormone Receptor Positive Breast Cancer
trastuzumab-anns
Sensitive
:
A1
HER-2 overexpression
Hormone Receptor Positive Breast Cancer
trastuzumab-anns
Sensitive
:
A1
HER-2 amplification
Hormone Receptor Positive Breast Cancer
trastuzumab-pkrb
Sensitive
:
A1
HER-2 overexpression
Hormone Receptor Positive Breast Cancer
trastuzumab-pkrb
Sensitive
:
A1
HR positive
Hormone Receptor Positive Breast Cancer
ribociclib
Sensitive
:
A1
HER-2 overexpression
Hormone Receptor Positive Breast Cancer
lapatinib
Sensitive
:
A1
ER positive
Estrogen Receptor Positive Breast Cancer
fulvestrant
Sensitive
:
A1
HER-2 overexpression
Hormone Receptor Positive Breast Cancer
neratinib
Sensitive
:
A1
HR positive
Hormone Receptor Positive Breast Cancer
olaparib
Sensitive
:
A1
HER-2 amplification
Hormone Receptor Positive Breast Cancer
neratinib
Sensitive
:
A1
ER positive
Estrogen Receptor Positive Breast Cancer
exemestane
Sensitive
:
A1
HR positive
Hormone Receptor Positive Breast Cancer
letrozole
Sensitive
:
A1
HR positive
Hormone Receptor Positive Breast Cancer
anastrozole
Sensitive
:
A1
ER positive
Estrogen Receptor Positive Breast Cancer
toremifene
Sensitive
:
A1
HR positive
Hormone Receptor Positive Breast Cancer
talazoparib
Sensitive
:
A1
HR positive
Hormone Receptor Positive Breast Cancer
fulvestrant
Sensitive
:
A1
HR positive
Hormone Receptor Positive Breast Cancer
palbociclib
Resistant
:
A2
HR positive
Hormone Receptor Positive Breast Cancer
everolimus
Sensitive
:
A2
HR positive
Hormone Receptor Positive Breast Cancer
Aromatase inhibitor + palbociclib
Sensitive
:
A2
HR positive
Hormone Receptor Positive Breast Cancer
Aromatase inhibitor
Sensitive
:
A2
BRCA2 mutation
Hormone Receptor Positive Breast Cancer
PARP inhibitor
Sensitive
:
A2
BRCA1 mutation
Hormone Receptor Positive Breast Cancer
PARP inhibitor
Sensitive
:
A2
HR positive
Hormone Receptor Positive Breast Cancer
CDK6 inhibitor + Aromatase inhibitor
Sensitive
:
A2
HR positive
Hormone Receptor Positive Breast Cancer
CDK4 inhibitor + Aromatase inhibitor
Sensitive
:
A2
HR positive
Hormone Receptor Positive Breast Cancer
trastuzumab + lapatinib
Resistant
:
B
HR positive
Hormone Receptor Positive Breast Cancer
trastuzumab
Resistant
:
B